Phaseline

Targets › MIR-23B

MIR-23B: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Jul 2027.

Open in Phaseline: the race on MIR-23B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ARTHEx BiotechATX-01
miR-23b inhibitor (synthetic single-stranded oligonucleotide/anti-miR)
MIR-23BPhase 1Myotonic Dystrophy 1Jul 2027

Conditions

Myotonic Dystrophy 1 (1)

Modalities

small molecule (1)

Companies

ARTHEx Biotech (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.